Related Experiment Video
Updated: Jun 26, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Briefing on Investigational Chimeric Antigen Receptor T-Cell Immunotherapies in Pediatric Neoplasms
Brielle Stawicki1,2, Tyler Schacher1,3, Anna Dushenkov1
1Fairleigh Dickinson University School of Pharmacy, Florham Park, NJ, USA.
Abstract:
The promising results seen in the treatment of refractory hematologic malignancies with tisagenlecleucel (Kymriah), the pioneering Chimeric Antigen Receptor (CAR) T-cell immunotherapy, has stimulated a fast growth in research and clinical testing of novel CAR-T constructs, targets, and various generations of CAR T-cells. Pharmacists may receive inquiries about active clinical trials or may be contributing to the care of patients participating in these studies. This briefing discusses the on-going clinical trials that explore novel CAR T-cell immunotherapies in pediatric refractory malignancies of hematologic and solid organ origins. It can be valuable in assisting practitioners in navigating the rapidly evolving field of CAR T-cell immunotherapies.
Insights
Chimeric Antigen Receptor (CAR) T-cell therapy shows promise for refractory hematologic cancers. Ongoing clinical trials explore novel CAR T-cell immunotherapies for pediatric refractory malignancies, aiding practitioners in this evolving field.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Tisagenlecleucel (Kymriah), a Chimeric Antigen Receptor (CAR) T-cell immunotherapy, has demonstrated efficacy in refractory hematologic malignancies.
- This success has accelerated research into new CAR T-cell therapies, including different constructs, targets, and generations.
Purpose of the Study:
- To review ongoing clinical trials of novel CAR T-cell immunotherapies.
- Focus on pediatric refractory malignancies, encompassing both hematologic and solid organ origins.
- To provide a resource for healthcare practitioners, particularly pharmacists, managing patients in CAR T-cell trials.
Main Methods:
- Review of current clinical trials involving novel CAR T-cell therapies.
- Inclusion criteria focus on pediatric refractory malignancies.
- Discussion of CAR T-cell constructs, targets, and therapeutic advancements.
Main Results:
- The field of CAR T-cell therapy is rapidly expanding with numerous ongoing clinical investigations.
- Emerging CAR T-cell strategies are being tested in pediatric populations with challenging malignancies.
- These trials represent the next wave of innovation in cancer immunotherapy.
Conclusions:
- Novel CAR T-cell immunotherapies are under active clinical investigation for pediatric refractory malignancies.
- Practitioners require updated information to support patients participating in these advanced trials.
- The evolution of CAR T-cell therapy offers new hope for difficult-to-treat cancers.
